Upstream Bio (UPB) Projected to Post Quarterly Earnings on Wednesday

Upstream Bio (NASDAQ:UPB) will likely be issuing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Upstream Bio to announce earnings of ($0.7286) per share and revenue of $0.52 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 7:00 AM ET.

Upstream Bio (NASDAQ:UPB) last announced its earnings results on Tuesday, August 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.01. The company had revenue of $0.77 million for the quarter, compared to the consensus estimate of $0.56 million. On average, analysts expect Upstream Bio to post ($2.84) EPS for the current fiscal year and ($2.77) EPS for the next fiscal year.

Upstream Bio Price Performance

NASDAQ:UPB opened at $2.79 on Wednesday. The stock has a market cap of $152.81 million, a P/E ratio of -0.96 and a beta of 1.38. Upstream Bio has a one year low of $2.68 and a one year high of $33.68. The company has a fifty day moving average price of $5.16 and a 200 day moving average price of $9.90.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Upstream Bio from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Friday, August 14th. Weiss Ratings upgraded shares of Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of Upstream Bio in a research report on Wednesday, September 2nd. Truist Financial reduced their target price on shares of Upstream Bio to $25.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Finally, Wall Street Zen downgraded Upstream Bio from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $29.67.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on developing therapies for inflammatory and immune-mediated diseases. The company’s research is centered on targeting pathways involved in type 2 inflammation, which contributes to conditions affecting the respiratory system and other tissues.

Its lead product candidate is verekitug, an investigational, long-acting monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a role in initiating and maintaining allergic and inflammatory responses.